Contact
Ettore Diaferia – e.diaferia@itelte.it
Michael Kuckeland – m.kuckeland@cspect.eu
Company
circumSPECT was founded in 2016 by Michael Kuckeland, shareholder and CEO of this start-up enterprise. 2021 ITEL Pharma became second shareholder and Ettore Diaferia second CEO.
Since 2016, all activities of the company are focused on the devolopment of PSMA-Tracers.
In 2016, Prof. Bernd Neumaier, chair of his department at the Research Centre Jülich (Germany) together with his colleagous and in cooperation with the University Hospital of Nuclear Medicine Cologne (chair Prof. Alexander Drzezga) developed a new 18F-PSMA Tracer.
Later the University Hospital of Cologne was granted two patents in Europe and in the United States.
2017 CSPECT became exclusive global licensee of this innovative PSMA specific tracer.
Since then, Prof. Drzezga collected extensive clinical experience with this tracer, regularly produced in Jülich, with thousands of patients for several years now. Several publications complete his positive view on this tracer. Most relevant information about this tracer can be found here: 18f-jk-psma-7 - Google Suche
CSPECT is happy, to have found the new Partner ITEL Pharma in 2021 for the common further development 18F-JK-PSMA-7.
Consequently, clinical trial phase III started in 2022 and was successfully finished in January 2024.
Entry into the European Pharmacopoeia (Ph. Eur.) is expected.
Now the procedure of Marketing Authorization in several Euroean countries is being started.